Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
<h4>Background</h4> <p>Vedolizumab specifically recognizes the 47 integrin and selectively blocks gut lymphocyte trafficking: potentially, it offers gut-specific immunosuppression. </p> <h4>Aims</h4> <p>To review the safety of vedolizumab and summarise p...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2017
|